The dilemma of the prolonged QT interval in early drug studies

British Journal of Clinical Pharmacology

Volumn 41, Issue 2, 1996, Pages 77-81

  Thomas, M ^a   Maconochie, J G ^a   Fletcher, E ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Early drug studies; Healthy subjects; QT interval prolongation

Indexed keywords

ACECAINIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; BEPRIDIL; BRETYLIUM; CHLOROQUINE; CISAPRIDE; DISOPYRAMIDE; ERYTHROMYCIN; FENOTEROL; FUROSEMIDE; HALOFANTRINE; KETANSERIN; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; PREDNISOLONE; PRENYLAMINE; PROCAINAMIDE; QUINIDINE; SALBUTAMOL; SOTALOL; TERBUTALINE; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; REVIEW;

EID: 0030066942     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00163.x     Document Type: Review

References (51)

1. Jervell A, Lange-Neilsen F. Congenital deafness, functional heart disease with prolongation of QT interval. Am Heart J 1957; 54: 59-68.
2. Moss AJ, Schwartz MD. Delayed repolarisation. (QT or QTa Prolongation) and malignant ventricular arrhythmias. Modern Concepts of Cardiovascular Disease 1982; 51: 85-89.
3. Algra A, Tijssen J, Roelandt J, Pool J, Lubsen J. QTc prolongation measured by standard 12-Lead electrocardiogram is an independent risk factor for sudden death. Circulation 1991; 83: 188-189.
4. Schouten E, Dekker J, Meppelink P, Kok F, Vanderbroucher J, Paol J. QT-interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991; 84: 1516-1523.
5. Dessertene F. La tachycardie ventriculaire à deux foyers opposé variables. Archives des Maladies du Coeur et des Vaisseaux 1966; 59: 263-272.
6. Jackman WM, Friday JJ, Anderson JL, Aliot EM, Clark M, Lazzard R. The long QT syndromes: a critical review, new clinical observations, and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115-172.
7. Waldo AL, Wit AL. Mechanism of cardiac arrhythmias. Lancet 1993; 341: 1189-1193.
8. Surawicz B, Knoebel SB. Long QT: good, bad or indifferent. J Am Coll Cardiol 1984; 4: 398-413.
9. Han J, Soel BG. Electrophysiological precursors of ventricular tachyarrhythmias. Arch Intern Med 1972; 129: 749-755.
10. Thomas Simon HL. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev 1994; 13: 77-102.
11. Faber Thomas S, Zehender Manfred, Just Hanjörg. Drug-induced torsade de pointes incidence, management and prevention. Drug Safety 1994; 11: 463-476.
12. Roden DM, Woosley RL, Primm RP. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986; 111: 1088-1093.
13. Strasberg B, Sclarovsky S, Erdberg A, et al. Procainamide-induced polymorphous ventricular tachycardia. Am J Cardiol 1981; 47: 1309-1314.
14. Singh BN, Vaughan-Williams EM. Classification of antiarrhythmic drugs. In Symposium on cardiac arrhythmias, eds Sandoe E, Flensted-Jensen, Olesen KH. Sodertalje. AB. Astra. 1970.
15. Ben-David J, Zipes DP. Torsade de pointes and proarrhythmia. Lancet 1993; 341: 1578-1582.
16. Nyuyen PT, Scheinmann MM, Segar J. Polymorphous ventricular tachycardia: Clinical characterisation, therapy and the QT interval. Circulation 1986; 74: 340-349.
17. Gimeno G, Vicario A, Lugones M, et al. Prolonged QT interval and arrhythmogenic action of prenylamine. Rev Argent Cardiol 1980; 48: 337-338.
18. Funck-Brentano C, Coudray P, Planellas J, Motte G, Jaiilon P. Effects of bepridil and diltiazem on ventricular repolarisation in angina pectoris. Am J Cardiol 1990; 66: 812-817.
19. Cassem N. Cardiovascular effects of anti-psychotic drugs. J Clin Psychol 1982; 43: 22-28.
20. Fowler NO, McCall D, Chou T, et al. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotrophic drugs. Am J Cardiol 1976; 37: 223-230.
21. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie JW. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987; 144: 673-675.
22. Kounis NG. Iatrogenic 'Torsade de pointes' ventricular tachycardia. Postgrad Med J 1979; 55: 832.
23. Lipworth BJ, McDevitt DG, Struthers AD. Electrocardiographic changes induced by inhaled salbutamol after treatment with bendrofluazide: effects of replacement therapy with potassium, magnesium and triamterene. Clin Sci 1990; 78: 255-259.
24. Wong CS, Pavorid ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular and hypokalaemic effects of fenoterol, salbutamol and terbutaline in asthma. Lancet 1990; 336: 1396-1399.
25. 2-serotonergic antagonist, ketanserin, in humans. Cardiovascular Drugs and Therapy 1990; 4: 1157-1160.
26. Ahmad RS, Wolfe SM. Cisapride and Torsade de pointes. Lancet 1995; 345: 508.
27. McConnell TJ, Stanners AJ. Torsade de pointes complicating therapy with terfenadine. Br Med J 1991; 302: 1469.
28. Wiley JF, Gelber ML, Henretig FM, Wiley CC, Sandu S, Loiselle J. Cardiotoxic effects of aztemizole overdose in children. J Paediatrics 1992; 120: 799-802.
29. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsade de pointes). Br Med J 1990; 300: 1375-1376.
30. Hauchier JP, Lanfranchi J, Ginies G, Raynaud R. Syncope through multifocal ventricular tachycardia during treatment with chloroquine: study of the hisian electrogram and treatment by verapamil. Ann Cardiol Angiol 1974; 23: 341-345.
31. Karbwang J, Na Bandchang K, Bunnag D, Harinasuta T, Laothavorn. Cardiac effect of halofantrine. Lancet 1993; 342: 501-?.
32. Nyuyen PT, Scheinman MM, Segar J. Polymorphous ventricular tachycardia: Clinical characterization, therapy, and the QT interval. Circulation 1986; 74: 340-349.
33. Hii JTY, Wyse DG, Gillis AM, Duff HJ, Salylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86: 1374-1383.
34. Lepeschkin E, Suraweiz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1958; 6: 378-388.
35. Moss AJ. Measurement of the QT interval and the risk associated with QTc prolongation: A review. Am J Cardiol 1993; 72: 23B-25B.
36. Christinason JL, Guccione P, Garson A. Differences in QT measurement on ambulatory and standard electrocardiography. Proceedings of the Fifth International Congress of Ambulatory Monitoring. 1992.
37. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-367.
38. Sarma JSM, Sarma RJ, Bilitch M, et al. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: re-evaluation of the Bazett's formula. Am J Cardiol 1984; 54: 103-108.
39. Rautaharjer PM, Waren JW, Calhoun HP. Estimation of QT prolongation; a persistent, avoidable error in computer electrocardiography. J Electrocardiol 1990; 23 (suppl): 111-117.
40. Ahnve S. Correction of the QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J 1985; 109: 568-574.
41. Comprehensive Electrocardiography: Theory and Practice in Health and Disease. First Edition, eds, MacFarlane PW, Lawrie TDV. Oxford, England, Pergamon, Press. 1989. vol. 3. 1142.
42. Puddu PE, Jouve R, Marriotti S et al. Evaluation of 10 QT prediction formulas in 881 middle-aged men from the Seven Countries Study. Emphasis on the cubic root Fridericia's equation. J Electrocardiol 1988; 21: 219-229.
43. Morganroth J, Brozovich FV, McDonald JT, et al. Variability of the QT measurement in healthy men with implications for selection of an abnormal QT value to predict drug toxicity and pro-arrhythmia. Am J Cardiol 1991; 67: 774-776.
44. Gunput MD, Williams P, Yogendran L, Keene ON, Maconochie JG. Qtc, PR interval and heart rate variability in healthy volunteers - a review of 12-lead ECG data from clinical pharmacology studies. Br J Clin Pharmacol 1995; 39: 577P.
45. Karen A, Tzivoni D, Gavish D, et al. Etiology warning signs and therapy of Torsade de Pointes: a study of 10 patients. Circulation 1981; 64: 1167-1174.
46. Hariman RJ, Wang Y, Sharif MA, et al. Early afterdepolarizations arising from M cells in intact dogs [abstract]. Circulation 1992; 86 Suppl:
47. Drouin E, Charpentier F, Gauthier C, et al. Evidence for the presence of M cells in the human ventricle [abstract]. PACE 1993; 16 Suppl II: 876.
48. Antzelevitch C, Skouri MD. Clinical relevance of cardiac arrythmias generated by afterdepolarizations. Role of M cells in the generation of U waves. Triggered activity and Torsade de Pointes. J Am Coll Cardiol 1994; 23: 259-277.
49. Ventricular arrhythmias due to terfenadine and astemizole. Committee on Safety of Medicines. Current Problems No. 35. November 1992.
50. Stop Press: Cisapride (Prepulsid, Alimix) - interaction with ketoconazole and cardiotoxicity. Committee on Safety of Medicines/Medicines Control Agency. Current Problems in Pharmacovigilance 1995; 21: 1.
51. Botstein P. Is QT interval prolongation harmful? A regulatory perspective. Am J Cardiol 1993; 72: 50B-52B.